Nguyen, Lien D. http://orcid.org/0000-0001-8096-1570
Fischer, Tom T. http://orcid.org/0000-0002-2138-9102
Ehrlich, Barbara E. http://orcid.org/0000-0001-9657-9704
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK057751)
Article History
Received: 8 July 2020
Accepted: 9 June 2021
First Online: 26 June 2021
Declarations
:
: The animal protocol followed the recommendations in the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals and was approved by the Institutional Animal Care and Use Committee at Yale University.
: All authors consented to the publication of the manuscript.
: B.E.E is a founder of Osmol Therapeutics, a company that is targeting NCS1 for therapeutic purposes. The remaining authors have declared that no conflict of interest exists.